Accueil   Diary - News   All news ERYTECH submits marketing authorization application

ERYTECH submits marketing authorization application

ERYTECH Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ERY-ASP (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).

 

Read the press release